Previous 10 | Next 10 |
home / stock / phmmf / phmmf news
MADRID , April 17, 2018 /PRNewswire/ -- PharmaMar (MCE: PHM) has presented during the AACR meeting (American Association for Cancer Research) in Chicago new data about how plitidepsin works on the tumor cells. Under the title " eEF1A2 interacts with and inhibits PKR to enhance canc...
The following slide deck was published by Pharma Mar SA in conjunction with this Read more ...
MADRID , March 26, 2018 /PRNewswire/ -- PharmaMar (MCE: PHM), today announced it will be featured as a presenting company at the 17th Needham & Co Annual Healthcare Conference. The conference is being held on March 27-28 at the Westin New York Grand Central hotel in New York...
Note: Subscribers to Avisol Capital Partners Total Pharma Tracker got an early look at this publication. Welcome to another edition of "3 Things In Biotech," a daily digest dedicated to helping you keep pace with the fast-moving world of pharmaceutical and biotechnology research. Pro...
MADRID , Feb. 20, 2018 /PRNewswire/ -- Dr Anna Farago , oncologist from the Massachusetts General Hospital and principal investigator of the phase III ATLANTIS clinical trial, will present the potential of lurbinectedin in small-cell lung cancer along with the main clinical data on s...
MADRID , Feb. 16, 2018 /PRNewswire/ -- The antibody conjugates MI130004 is the result of combining trastuzumab with the molecule of marine origin belonging to PharmaMar, PM050489 The prestigious magazine Molecular Cancer Therapeutics, from the American Association for Cancer Resear...
MADRID , February 14, 2018 /PRNewswire/ -- PharmaMar (MCE: PHM) has announced today the signing of an exclusive licensing agreement with Seattle Genetics Inc. (SGEN: NASDAQ GS) under which Seattle Genetics receives exclusive worldwide rights to certain PharmaMar proprietary molecu...
MADRID , January 3, 2018 /PRNewswire/ -- PharmaMar (MCE: PHM) has announced the initiation of the re-examination process by the European Medicines Agency (EMA) for Aplidin® (plitidepsin) for the indication of relapsed and refractory multiple myeloma. (Log...
MADRID , January 2, 2018 /PRNewswire/ -- PharmaMar (MCE:PHM) has announced today a commercialization and distribution license agreement with Megapharm Ltd. for the marine-derived anticancer drug Aplidin
MADRID , January 2, 2018 /PRNewswire/ -- PharmaMar (MCE: PHM) has announced today a commercialization and distribution license agreement with Megapharm Ltd. for the marine-derived anticancer drug Aplidin
News, Short Squeeze, Breakout and More Instantly...
SunPower Corporation (SPWR) is expected to report $-0.29 for Q1 2024 Siemens Healthineers AG ADR (SMMNY) is expected to report for Q2 2024 Specificity Inc Com (SPTY) is expected to report for Q1 2024 Tokyo Gas Co. Ltd. ADR (TKGSY) is expected to report for Q4 2024 Gol Linhas Aerea...
Ebix Inc. (EBIXQ) is expected to report for Q1 2024 Amesite Inc. (AMST) is expected to report for Q3 2024 Hibbett Inc. (HIBB) is expected to report $2.68 for Q1 2025 Waterdrop Inc. American Depositary Shares (each representing the right to receive 10 Class A) (WDH) is expected to repo...
TDCX Inc. American Depositary Shares each representing one Class A (TDCX) is expected to report for Q1 2024 nCino Inc. (NCNO) is expected to report $0 for Q1 2025 SK Telecom Co. Ltd. (SKM) is expected to report for Q1 2024 Redeia Corporacion S.A. ADR (RDEIY) is expected to report for ...